Buy (150 RUB)
Generate QR code
Open Access
Subscription or Fee Access
Immunotherapy of acute lymphoblastic leukemia in children and adolescents: the beginning of a new era
https://doi.org/10.21508/1027-4065-2025-70-4-5-15
Abstract
Acute lymphoblastic leukemia is a malignant blood cancer primarily affecting children and adolescents. Traditionally, acute lymphoblastic leukemia treatment has relied on chemotherapy, but recent advances in immunotherapy have shown substantial potential for improving outcomes and reducing toxicity. This article explores the evolution of acute lymphoblastic leukemia treatment, with a particular focus on immunotherapeutic approaches such as bispecific antibodies (blinatumomab), antibody-drug conjugates (inotuzumab ozogamicin), and chimeric antigen receptor (CAR) T-cell therapy. These immunologic constructs have demonstrated promising results in improving survival rates and minimal residual disease negativity in acute lymphoblastic leukemia patients. The mechanisms of action, clinical applications, and limitations of these immunotherapies are discussed emphasizing their role in shaping a new era in acute lymphoblastic leukemia management.
About the Authors
A. I. Karachunsky
Dmitry Rogachev National Medical Research Center for Children’s Hematology, Oncology and Immunology; Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Moscow
Yu. V. Rumyantseva
Dmitry Rogachev National Medical Research Center for Children’s Hematology, Oncology and Immunology; Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Moscow
E. G. Mansurova
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Moscow
References
1. Hunger S.P., Mullighan, C.G. Acute Lymphoblastic Leukemia in Children. N. Engl. J. Med. 2015; 373: 1541–1552. DOI: 10.1056/NEJMra1400972
2. Alaggio R., Amador C., Anagnostopoulos I., Attygalle A.D., Araujo I.B.d.O., et al. The 5th Edition of the World Health Organization Classification of Haemato lymphoid Tumours: Lymphoid Neoplasms. Leukemia 2022; 36: 1720–1748. DOI: 10.1038/s41375–022–01620–2
3. Dong Y., Shi O., Zeng Q., Lu X., Wang W., Li Y., Wang Q. Leukemia incidence trends at the global, regional, and national level between 1990 and 2017. Exp Hematol Oncol. 2020; 9: 14. DOI: 10.1186/s40164–020–00170–6
4. Aur R.J., Simone J., Hustu H.O., Walters T., Borella L., et al. Central nervous system therapy and combination chemotherapy of childhood lymphocytic leukemia. Blood. 1971; 37(3): 272–281
5. Riehm H., Gadner H., Henze G., Kornhuber B., Lampert F., Niethammer D., et al. Results and significance of six randomized trials in four consecutive ALL-BFM studies. Haematol Blood Transfus. 1990; 33: 439–450. DOI: 10.1007/978–3–642–74643–7_81
6. Rumyntsev А., Krizhanovskiy О., Maschan А., Karachunskiy А., Samochatova Е. Intensive chemotherapy for acute leukemias (AL) in childhood with BFM protocols: Moscow experices 1990–1992. First successes and failures. Annals of Hematology Suppelement 1992; 64: 806
7. von Stackelberg A., Karachunskiy A., Kudryashova Ju., Miakova N., Belikova L., Rumiantzev A., et al. Toxicity, supportive care and costs of two chemotherapy protocols for treatment of childhood ALL in Russia: BFM 90m and MB 91. Eur J Cancer. 1999; 35(9): 1349–1355. DOI: 10.1016/s0959–8049(99)00112–4
8. Karachunskiy A., Herold R., von Stackelberg A., Miakova N., Timakov A., Henze G., et al. Results of the first randomized multicentre trial on childhood acute lymphoblastic leukaemia in Russia. Leukemia Springer Nature 2008; 22(6): 1144–1153. DOI: 10.1038/leu.2008.63
9. Schmiegelow K., Attarbaschi A., Barzilai S., Escherich G., Frandsen T.L., Halsey C., et al; Ponte di Legno toxicity working group. Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus. Lancet Oncol 2016; 17(6):e231–e239. DOI: 10.1016/S1470–2045(16)30035–3
10. Kohler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495–497. DOI: 10.1038/256495a0
11. Aldeghaither D.S., Zahavi D.J., Murray J.C., Fertig E.J., Graham G.T., Zhang Y.W., et al. Mechanism of resistance to antibody targeted immune attack. Cancer Immunol. Res. 2019; 7: 230–243. DOI: 10.1158/2326–6066.CIR-18–0266
12. Thiery J., Keefe D., Boulant S., Boucrot E., Walch M., Martinvalet D., et al. Perforin Pores in the Endosomal Membrane Trigger the Release of Endocytosed Granzyme B into the Cytosol of Target Cells. Nat. Immunol. 2011; 12: 770–777. DOI: 10.1038/ni.2050
13. Queudeville M., Ebinger M. Blinatumomab in Pediatric Acute Lymphoblastic Leukemia-From Salvage to First Line Therapy (A Systematic Review). J Clin Med. 2021; 10(12): 2544. DOI: 10.3390/jcm10122544
14. Su Z, Xiao D, Xie F, Liu L, Wang Y, Fan S, Zhou X, Li S. Antibody-drug conjugates: Recent advances in linker chemistry. Acta Pharm Sin B. 2021 Dec; 11(12): 3889–3907. DOI: 10.1016/j.apsb.2021.03.042
15. Kantarjian H.M., DeAngelo D.J., Stelljes M., Martinelli G., Liedtke M., et al. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. N Engl J Med. 2016; 375(8): 740–753. DOI: 10.1056/NEJMoa1509277
16. Park J.H., Riviére I., Gonen M., Wang X., Sénéchal B., Curran K.J., et al. Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia. N Engl J Med. 2018 Feb 1; 378(5): 449–459. DOI: 10.1056/NEJMoa1709919
17. Del Zotto G., Marcenaro E., Vacca P., Sivori S., Pende D., Della Chiesa M., et al. Markers and function of human NK cells in normal and pathological conditions. Cytometry B Clin Cytom. 2017; 92(2): 100–114. DOI: 10.1002/cyto.b.21508
18. Dustin M.L., Long E.O. Cytotoxic immunological synapses. Immunol Rev. 2010; 235(1): 24–34. DOI: 10.1111/j.0105–2896.2010.00904.x
Review
For citations:
Karachunsky A.I., Rumyantseva Yu.V., Mansurova E.G. Immunotherapy of acute lymphoblastic leukemia in children and adolescents: the beginning of a new era. Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics). 2025;70(4):5–15. (In Russ.) https://doi.org/10.21508/1027-4065-2025-70-4-5-15
Views:
89
Email this article 